SCHEMBL1966882

SCHEMBL1966882

CCOC(=O)c1c(O)c2cccn2n(Cc2c(F)cccc2F)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
KDM4E B2RXH2 6/20 0.46
RECQL P46063 1/20 0.44
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.41
PTGES O14684 1/20 0.41
ALOX5 P09917 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
CFTR P13569 2/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968107 0.88 KDM4E (0.50) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1965910 0.85 ALDH1A1 (0.47) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1966018 0.84 LMNA (0.49) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1968973 0.83 ALDH1A1 (0.43) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1967350 0.83 KDM4E (0.54) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1967127 0.81 KDM4E (0.48) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1966103 0.80 KMT2A (0.50) ALDH1A1KDM4ERECQLLMNAPTGES
SCHEMBL1966099 0.80 KDM4E (0.44) ALDH1A1KDM4ERECQLLMNAHTT
SCHEMBL1966458 0.80 KDM4E (0.46) ALDH1A1KDM4ERECQLMEN1KMT2A
SCHEMBL1967538 0.80 KDM4E (0.63) ALDH1A1KDM4ERECQLLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 ALDH1A1 268/4885KDM4E 471/4885RECQL 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.